Recent Investment Analysts’ Ratings Updates for BioAge Labs (BIOA)

BioAge Labs (NASDAQ: BIOA) recently received a number of ratings updates from brokerages and research firms:

• 10/11/2026 – BioAge Labs is now covered by UBS Group AG. They set a “neutral” rating and a $8.00 price target on the stock.
• 10/11/2026 – BioAge Labs was upgraded by UBS Group AG to “hold”.
• 10/10/2026 – BioAge Labs was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 10/8/2026 – BioAge Labs was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 9/13/2026 – BioAge Labs was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 9/9/2026 – BioAge Labs had its “buy” rating reaffirmed by Roth Capital. They now have a $25.00 price target on the stock.
• 9/8/2026 – BioAge Labs had its “buy” rating reaffirmed by BTIG Research. They now have a $40.00 price target on the stock.
• 9/5/2026 – BioAge Labs was downgraded by Wall Street Zen from “sell” to “strong sell”.

BioAge Labs, Inc is a clinical-stage biotechnology company focused on developing medicines for diseases associated with aging. The company uses human longevity data, machine learning and biology research to identify therapeutic targets and develop treatments intended to address the biological drivers of aging and age-related decline.

BioAge’s pipeline has included azelaprag, formerly known as BGE-105, an investigational small-molecule agonist of the apelin receptor. The company has evaluated azelaprag in clinical studies involving muscle function and has also investigated its potential use in combination with incretin-based medicines for obesity.